AstraZeneca Out-licenses US Rights for its COPD Drugs to Circassia
By Jasmine Kalsi
Pharma Deals Review: Vol 2017 Issue 4 (Table of Contents)
Published: 22 Apr-2017
DOI: 10.3833/pdr.v2017.i4.2240 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
AstraZeneca (AZ) has divested the US rights to two of its chronic obstructive pulmonary disease (COPD) drugs to Circassia in a deal worth up to US$300 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
PharmaDeals has now moved to a new platform (https://analyticslink.customerportal.iqvia.com). The current PharmaDeals website will be disabled from October 31, 2026. Please update your bookmarks and, if you have any issues accessing the new platform, please contact your IQVIA account manager.
RSS